Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis

[1]  Janet S. Lee,et al.  Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Achilefu,et al.  First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging , 2022, The Journal of Nuclear Medicine.

[3]  A. McMillan,et al.  [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  H. Kauczor,et al.  Fibroblast Activation Protein–Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.

[5]  S. Tavakoli,et al.  Imaging Immunometabolism in Atherosclerosis , 2021, The Journal of Nuclear Medicine.

[6]  M. Horton,et al.  Immune dysregulation as a driver of idiopathic pulmonary fibrosis. , 2021, The Journal of clinical investigation.

[7]  H. Chu,et al.  Very Late Antigen-4: A Novel Receptor for Club Cell Secretory Protein 16 to Control Inflammation , 2021, American journal of respiratory and critical care medicine.

[8]  C. Anderson,et al.  Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury , 2020, The Journal of Nuclear Medicine.

[9]  T. Wynn,et al.  Fibrosis: from mechanisms to medicines , 2020, Nature.

[10]  C. Anderson,et al.  Integrin VLA-4 as a PET imaging biomarker of hyper-adhesion in transgenic sickle mice. , 2020, Blood advances.

[11]  V. Cottin,et al.  Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.

[12]  M. Kreuter,et al.  Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. , 2020, The Lancet. Respiratory medicine.

[13]  I. Wilkinson,et al.  Advances in PET to assess pulmonary inflammation: A systematic review. , 2020, European journal of radiology.

[14]  R. Gropler,et al.  Chemokine receptor 2-targeted molecular imaging in pulmonary fibrosis , 2020, bioRxiv.

[15]  D. Laskin,et al.  Role of Macrophages in Acute Lung Injury and Chronic Fibrosis Induced by Pulmonary Toxicants , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[16]  V. Fineschi,et al.  Searching for highly sensitive and specific biomarkers for sepsis: State-of-the-art in post-mortem diagnosis of sepsis through immunohistochemical analysis , 2019, International journal of immunopathology and pharmacology.

[17]  C. Laymon,et al.  Combined VLA-4–Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma , 2018, The Journal of Nuclear Medicine.

[18]  M. Mack.  Inflammation and fibrosis. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[19]  J. Flynn,et al.  Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α4β1–Expressing Immune Cells , 2017, The Journal of Immunology.

[20]  P. Caravan,et al.  Optimization of a Collagen-Targeted PET Probe for Molecular Imaging of Pulmonary Fibrosis , 2017, The Journal of Nuclear Medicine.

[21]  R. Gropler,et al.  PET-based Imaging of Chemokine Receptor 2 in Experimental and Disease-related Lung Inflammation. , 2017, Radiology.

[22]  M. Mino‐Kenudson,et al.  Type I collagen–targeted PET probe for pulmonary fibrosis detection and staging in preclinical models , 2017, Science Translational Medicine.

[23]  L. Murray,et al.  Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? , 2017, Pharmacology & therapeutics.

[24]  R. Gropler,et al.  Noninvasive Imaging of CCR2+ Cells in Ischemia‐Reperfusion Injury After Lung Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  M. Breshears,et al.  A Critical Role for P2X7 Receptor–Induced VCAM-1 Shedding and Neutrophil Infiltration during Acute Lung Injury , 2016, The Journal of Immunology.

[26]  A. Gaggar,et al.  Matrix Remodeling in Pulmonary Fibrosis and Emphysema. , 2016, American journal of respiratory cell and molecular biology.

[27]  H. Collard,et al.  Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. , 2016, American journal of respiratory and critical care medicine.

[28]  M. Cosio,et al.  Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis , 2016, PloS one.

[29]  Walter J. Akers,et al.  Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents , 2016, The Journal of Nuclear Medicine.

[30]  T. Maher,et al.  Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease? , 2016, Trends in molecular medicine.

[31]  J. Tedrow,et al.  VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. , 2015, Cellular signalling.

[32]  C. Anderson,et al.  Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. , 2015, Molecular pharmaceutics.

[33]  C. Anderson,et al.  PET Imaging of Very Late Antigen-4 in Melanoma: Comparison of 68Ga- and 64Cu-Labeled NODAGA and CB-TE1A1P-LLP2A Conjugates , 2014, The Journal of Nuclear Medicine.

[34]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[35]  T. Mustelin,et al.  Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes , 2013, Fibrogenesis & tissue repair.

[36]  Reto Asmis,et al.  Bioenergetic Profiles Diverge During Macrophage Polarization: Implications for the Interpretation of 18F-FDG PET Imaging of Atherosclerosis , 2013, The Journal of Nuclear Medicine.

[37]  G. Downey,et al.  The fibroproliferative response in acute respiratory distress syndrome: mechanisms and clinical significance , 2013, European Respiratory Journal.

[38]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[39]  J. Walrath,et al.  The α4β1 integrin in localization of Mycobacterium tuberculosis-specific T helper type 1 cells to the human lung. , 2011, American journal of respiratory cell and molecular biology.

[40]  N. Hogg,et al.  The Integrins Mac-1 and α4β1 Perform Crucial Roles in Neutrophil and T Cell Recruitment to Lungs during Streptococcus pneumoniae Infection , 2011, The Journal of Immunology.

[41]  K. Lam,et al.  An alpha4beta1 integrin antagonist decreases airway inflammation in ovalbumin-exposed mice. , 2009, European journal of pharmacology.

[42]  G. Raghu,et al.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. , 2008, American journal of respiratory and critical care medicine.

[43]  F. Martinez,et al.  An essential role for fibronectin extra type III domain A in pulmonary fibrosis. , 2008, American journal of respiratory and critical care medicine.

[44]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[45]  Kit S Lam,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. , 2006, Nature chemical biology.

[46]  W. Hagmann,et al.  A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. , 2003, American journal of respiratory and critical care medicine.

[47]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[48]  S. Tasaka,et al.  Very late antigen-4 in CD18-independent neutrophil emigration during acute bacterial pneumonia in mice. , 2002, American journal of respiratory and critical care medicine.

[49]  H. Yagita,et al.  The alpha 4 beta 1 (very late antigen (VLA)-4, CD49d/CD29) and alpha 5 beta 1 (VLA-5, CD49e/CD29) integrins mediate beta 2 (CD11/CD18) integrin-independent neutrophil recruitment to endotoxin-induced lung inflammation. , 2001, Journal of immunology.

[50]  M. Tsokos,et al.  Post-mortem markers of sepsis: an immunohistochemical study using VLA-4 (CD49d/CD29) and ICAM-1 (CD54) for the detection of sepsis-induced lung injury , 2001, International Journal of Legal Medicine.

[51]  A. Joetham,et al.  Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice. , 2000, American journal of respiratory and critical care medicine.

[52]  Carl G. Feng,et al.  Up-Regulation of VCAM-1 and Differential Expansion of β Integrin-Expressing T Lymphocytes Are Associated with Immunity to Pulmonary Mycobacterium tuberculosis Infection1 , 2000, The Journal of Immunology.

[53]  A. Castagnaro,et al.  The increased number of very late activation antigen-4-positive cells correlates with eosinophils and severity of disease in the induced sputum of asthmatic patients. , 2000, The Journal of allergy and clinical immunology.

[54]  M. Miyasaka,et al.  Blood monocyte migration to acute lung inflammation involves both CD11/CD18 and very late activation antigen-4-dependent and independent pathways. , 1998, Journal of immunology.

[55]  Y. Hasegawa,et al.  Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. , 1995, Chest.

[56]  S..  Role of Fibronectin in Fibrotic Lung Disease * A Growth Factor for Human Lung Fibroblasts , 2022 .